(NASDAQ: TLSI) Trisalus Life Sciences's forecast annual revenue growth rate of 44.04% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 8%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.68%.
Trisalus Life Sciences's revenue in 2025 is $32,141,000.On average, 3 Wall Street analysts forecast TLSI's revenue for 2025 to be $1,676,757,923, with the lowest TLSI revenue forecast at $1,652,427,471, and the highest TLSI revenue forecast at $1,697,834,225. On average, 3 Wall Street analysts forecast TLSI's revenue for 2026 to be $2,501,155,388, with the lowest TLSI revenue forecast at $2,364,935,125, and the highest TLSI revenue forecast at $2,591,968,897.
In 2027, TLSI is forecast to generate $3,819,843,214 in revenue, with the lowest revenue forecast at $3,819,843,214 and the highest revenue forecast at $3,819,843,214.